Your browser doesn't support javascript.
loading
Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group.
Laukhtina, Ekaterina; Moschini, Marco; Soria, Francesco; Andrea, David D; Teoh, Jeremy Yuen-Chun; Mori, Keiichiro; Albisinni, Simone; Mari, Andrea; Krajewski, Wojciech; Cimadamore, Alessia; Abufaraj, Mohammad; Enikeev, Dmitry; Neuzillet, Yann; Giannarini, Gianluca; Xylinas, Evanguelos; Kamat, Ashish M; Roupret, Morgan; Babjuk, Marko; Witjes, J Alfred; Shariat, Shahrokh F; Pradere, Benjamin.
Afiliação
  • Laukhtina E; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
  • Moschini M; Department of Urology and Division of Experimental Oncology, Urological Research Institute, Vita-Salute San Raffaele, Milan, Italy.
  • Soria F; Division of Urology, Department of Surgical Sciences, San Giovanni Battista Hospital, University of Studies of Torino, Torino, Italy.
  • Andrea DD; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
  • Teoh JY; S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong, Hong Kong, China.
  • Mori K; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Albisinni S; Service d'Urologie, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles, Belgium.
  • Mari A; Department of Urology, Careggi Hospital, University of Florence, Florence, Italy.
  • Krajewski W; Department of Minimally Invasive and Robotic Urology, University Center of Excellence in Urology, Wroclaw Medical University, Wroclaw, Poland.
  • Cimadamore A; Section of Pathological Anatomy, Marche Polytechnic University, School of Medicine, United Hospitals, Ancona, Italy.
  • Abufaraj M; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
  • Enikeev D; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.
  • Neuzillet Y; Department of Urology, Hôpital Foch, UVSQ-Paris-Saclay University, Suresnes, France.
  • Giannarini G; Urology Unit, University Hospital Santa Maria della Misericordia, Udine, Italy.
  • Xylinas E; Department of Urology, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, Paris, France.
  • Kamat AM; Department of Urology, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA.
  • Roupret M; GRC n°5, Predictive Onco-Urology, Ap-Hp, Urology, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France.
  • Babjuk M; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Second Faculty of Medicine, Hospital Motol, Charles University, Prague, Czech Republic.
  • Witjes JA; Department of Urology, Radboud University, Nijmegen Heyendaal, The Netherlands.
  • Shariat SF; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jord
  • Pradere B; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. Electronic address: benjaminpradere@gmail.com.
Eur Urol Focus ; 8(6): 1635-1642, 2022 11.
Article em En | MEDLINE | ID: mdl-35337773
ABSTRACT
CONTEXT Surveillance of the urethra and management of urethral recurrence (UR) after radical cystectomy (RC) is an area with poor evidence.

OBJECTIVE:

We aimed to summarize the available evidence and provide clinicians with practical recommendations on how to prevent and manage UR after RC for bladder cancer. EVIDENCE ACQUISITION The MEDLINE and EMBASE databases were searched during September 2021 for studies evaluating UR after RC. The primary endpoint was oncologic outcomes for patients who experienced UR depending on different surveillance and management approaches. EVIDENCE

SYNTHESIS:

Forty-three studies were included in the quantitative synthesis. According to the currently available literature, a tight-knitted surveillance protocol should be implemented for males treated with RC and nonorthotopic neobladder diversion as well as patients with prostatic involvement, tumor multifocality, bladder neck involvement, and concomitant carcinoma in situ. A survival benefit of a prophylactic urethrectomy has been reported only in patients at very high risk for UR based on clinical factors. Surveillance protocols were highly heterogeneous and poorly documented among included studies. Patients whose UR was diagnosed based on clinical symptoms had a poor prognosis. Only limited data were available on the comparative effectiveness of watchful waiting after RC versus clinical symptom screening as part of a follow-up strategy. However, the use of regular cytology and/or urethroscopy seems useful in select patients at high risk for UR. Despite limited data on the optimal management of UR, urethra-sparing approaches (transurethral resection of UR) seem to be an option for Ta (only) recurrences; a salvage urethrectomy with or without chemotherapy should be the standard for all others.

CONCLUSIONS:

Based on the currently available literature, we have proposed an algorithm to guide the decision-making process to help identify and treat UR after RC. Given the lack of evidence on how to deal with UR and surveil patients at risk for UR, this study may invigorate research in this area of unmet need. PATIENT

SUMMARY:

Early diagnosis and tailored management of urethral recurrence could help improve oncologic outcomes in these patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Eur Urol Focus Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Federação Russa

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies / Screening_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Eur Urol Focus Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Federação Russa